Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

81.88 -0.28 (-0.35%)
Streaming Delayed Price Updated: 12:04 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Edwards Lifesciences

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Top gainers and losers in the S&P500 index during Thursday's after-hours session. ↗
Via Chartmill
Edwards Lifesciences Corp (NYSE:EW) Shares Surge After Q1 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Topics Lawsuit
News headline image
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a... 
Via Finterra
Topics Economy Lawsuit Product Recall
Edwards Lifesciences Corp (NYSE:EW) Reports Mixed Q4 Results, Misses EPS Estimates ↗
Via Chartmill
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials. 
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire... 
Via MarketMinute
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
The Return of the Mega-Deal: How 2026’s Regulatory Pragmatism is Reshaping Corporate America
The U.S. mergers and acquisitions (M&A) landscape has entered a definitive new era in early 2026, marked by what analysts are calling a "Strategic Rebound." After years of aggressive antitrust... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
Unusual volume S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Edwards Lifesciences (EW) Earnings Transcript ↗
Edwards Lifesciences (EW) Earnings Transcript 
Via The Motley Fool
News headline image
The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for... 
Via MarketMinute
Topics Supply Chain
News headline image
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)... 
Via MarketMinute
News headline image
Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors ↗
Via MarketBeat
News headline image
The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Death of the Quick Deal: One Year Under the New FTC and DOJ Merger Regime
As we enter the early weeks of 2026, the American corporate landscape is still adjusting to a fundamental shift in the mechanics of growth. It has been nearly one year since the most significant... 
Via MarketMinute
Topics Economy
News headline image
The Thrombectomy Titan: Boston Scientific Shakes MedTech with $14.5 Billion Penumbra Acquisition
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era
As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2025 Dollar Rollercoaster: A Year-End Rally Masks a Historic Annual Retreat
As the final trading bells of 2025 ring out across Wall Street, the US Dollar is staging a defiant last-minute stand. After a year defined by dizzying volatility—ranging from a massive early-year surge... 
Via MarketMinute
Topics Economy World Trade
News headline image
Edwards Lifesciences Corp (NYSE:EW) Shows Strong Technical Setup for Potential Breakout ↗
Edwards Lifesciences (EW) shows strong technicals and a high-quality consolidation pattern, suggesting a potential breakout trade setup for chart-focused investors. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Edwards Lifesciences (EW) Earnings Transcript ↗
Edwards Lifesciences (EW) Earnings Transcript 
Via The Motley Fool
News headline image
EDWARDS LIFESCIENCES CORP (NYSE:EW) Shows Strong Technicals and a High-Quality Breakout Setup ↗
Edwards Lifesciences (EW) stock shows strong technical momentum and a high-quality breakout setup, poised for a potential move above key resistance. 
Via Chartmill
News headline image
Goodbye Nvidia, Hello Microsoft: Halvorsen's Big Q3 Hedge Fund Pivot ↗
Andreas Halvorsen of Viking Global Investors' portfolio Q3 changes included exits from Amazon, Nvidia and Qualcomm. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.